Author: Ravi Shankar

The ROG G1000 features a performance-driven design and the revolutionary ROG Thermal Atrium to push framerates to new heights

Fremont, CA, Sept. 22, 2026 (GLOBE NEWSWIRE) — Republic of Gamers (ROG) today announced that the ROG G1000, a flagship gaming desktop engineered to redefine the boundaries of performance, is now available for purchase and order. Powered by up to an AMD Ryzen™ 7 9800X3D CPU and our ROG Astral GeForce RTX™ 5080 GPU, the G1000 introduces the ROG Thermal Atrium—a specialized compartment decoupled from the main chassis to provide its 420mm AIO radiator with unrestricted access to cool ambient air. Combined with the groundbreaking AniMe Holo platform, the G1000 offers a whisper-quiet, high-performance experience housed in a commanding ultra tower built exclusively with premium ASUS and ROG components.

ROG G1000

 

AniMe Holo: A New Era of Personalization

Beyond its raw power, the ROG G1000 is a visual masterpiece featuring the all-new AniMe Holo technology. This system utilizes full-color holographic projectors, allowing gamers to personalize their desktop like never before. The side panel showcases a massive 380mm holographic fan with 720 LEDs, complemented by dual 215mm fans on the front panel.

Despite their scale, these fans operate at a whisper-quiet 20.5 dBA within their sealed housings. With support for 16.77 million colors and full integration via Armoury Crate, users can display custom text, system stats, or complex animations, creating a truly one-of-a-kind gaming machine.

 

Flagship Power and Uncompromising Specs

At the heart of the G1000 lies the AMD Ryzen™ 7 9800X3D. Featuring 16 cores, 32 threads, and advanced 3D V-Cache™ technology, this processor is designed to dominate AAA titles and intensive multitasking. Slated for later this year, ROG G1000 will also come equipped with the option of up to AMD Ryzen™ 9 9950X3D to complement your build.

 

To complement this elite processing power, the G1000 can be equipped with our ROG Astral GeForce RTX™ 5080 GPU. The system is built on a high-end X870 motherboard, featuring robust power delivery, onboard high-speed wireless, and dedicated TPM module for hardware-level security. With ultra-fast DDR5 RAM and four M.2 PCIe slots for massive storage expansion, the G1000 is prepared for the most demanding workloads of today and tomorrow.

 

Revolutionary ROG Thermal Atrium

The ROG G1000 debuts the ROG Thermal Atrium, a breakthrough in desktop cooling. By isolating the 420mm AIO radiator and three 140mm intake fans in a separate chamber outside the main chassis, the CPU cooler gains direct access to ambient air that hasn’t been heated by the GPU or PSU. This innovative layout reduces CPU intake temperatures by up to 16°C (28.8°F), ensuring absolute stability during marathon gaming sessions.

 

Following this Tri-Zone philosophy, the GPU and PSU sections are also thermally shielded from one another. The GPU draws fresh air from the front intakes, while the PSU maintains its own airflow path from beneath the chassis. Collectively, the G1000 thermal system can dissipate over 1000W of heat, providing the thermal headroom necessary for next-generation hardware and extreme performance.

 

The Pinnacle of Gaming Engineering

The ROG G1000 is more than just a gaming desktop; it is a statement of engineering excellence. By combining the revolutionary Thermal Atrium with world-class components and the mesmerizing AniMe Holo display, ROG continues to set the standard for what a flagship PC can achieve. For gamers and creators who refuse to compromise, the G1000 stands alone at the peak of performance.

Availability & Pricing

The ROG GM1000 is are available for purchase today from ASUS Store and our retailer partners: Amazon, BestBuy, ExcaliburPC, Newegg, and MicroCenter.

 

Retailer	Where to Buy
ASUS Online	Link
Amazon	Link
ExcaliburPC	Link
Newegg	Link
Microcenter	Link

 

 

Press Contacts: 

ASUS USA PR Team: asuspr_usa@asus.com 

 

Notes to Editors

ASUS USA Pressroom: https://www.asus.com/us/news/         

ASUS USA Facebook: https://www.facebook.com/asus.n.america/     

ASUS USA X (Twitter): https://twitter.com/ASUSUSA     

 

 

SPECIFICATIONS

	ROG G1000
Design	104L ATX Ultra Tower with “Anime Holo” holographic fan
Processor	•        AMD Ryzen™ 7 9800X3D / AMD Ryzen™ 9 9950X3D (Later Nov.-Dec.)
Graphics	UMA: Supports AMD Ryzen™ G-series •        NVIDIA® GeForce® RTX5080
Platform	•        AMD® X870 Chipset
Thermal	•        420mm AIO with “ROG Thermal Atrium” Cooling Chamber
Memory	•        4x DDR5 U-DIMM slots, memory max up to 128GB
SATA	•        2 x SATA 6.0Gb/s ports
Storage	•        Up to 4TB M.2 2280 NVMe™ PCIe® 4.0 Performance SSD
Front I/O Ports	•        2 x USB3.2 Gen1 5Gbps TypeA •        1 x USB Type-C® 10Gbps •        1 x Microphone (Black) •        1 x Headphone (Black)
Rear I/O Ports	•        2 x USB4® (40Gbps) ports (2 x USB Type-C®) •        1 x USB 10Gbps port (1 x Type-A) •        3 x USB 5Gbps ports (3 x Type-A) •        4 x USB 2.0 ports (4 x Type-A)  •        1 x HDMI™ port •        1 x Wi-Fi module •        1 x Realtek 2.5Gb Ethernet port •        3 x Audio jacks
Power Supply	•        1000W power supply (80+ Gold)
Dimension	11.4 × 22.9 × 24.2 in (290 x 582.7 x 614.8mm)
Weight	(88.18 lbs)  40KG

 

### 

About ROG 

Republic of Gamers (ROG) is an ASUS sub-brand dedicated to creating the world’s best gaming hardware and software. Formed in 2006, ROG offers a complete line of innovative products known for performance and quality, including motherboards, graphics cards, system components, laptops, desktops, monitors, smartphones, audio equipment, routers, peripherals and accessories. ROG participates in and sponsors major international gaming events. ROG gear has been used to set hundreds of overclocking records and it continues to be the preferred choice of gamers and enthusiasts around the world. To become one of those who dare, learn more about ROG at http://rog.asus.com. 

 

 

Press Inquiries

Anthony Spence
asuspr_usa [at] asus.com
https://www.asus.com/
48720 Kato Road | Fremont, CA 94538

A video accompanying this announcement is available here: https://youtube.com/watch?v=LhC_zCKTc20

The ROG G1000 features a performance-driven design and the revolutionary ROG Thermal Atrium to push framerates to new heights

Fremont, CA, Sept. 22, 2026 (GLOBE NEWSWIRE) — Republic of Gamers (ROG) today announced that the ROG G1000, a flagship gaming desktop engineered to redefine the boundaries of performance, is now available for purchase and order. Powered by up to an AMD Ryzen™ 7 9800X3D CPU and our ROG Astral GeForce RTX™ 5080 GPU, the G1000 introduces the ROG Thermal Atrium—a specialized compartment decoupled from the main chassis to provide its 420mm AIO radiator with unrestricted access to cool ambient air. Combined with the groundbreaking AniMe Holo platform, the G1000 offers a whisper-quiet, high-performance experience housed in a commanding ultra tower built exclusively with premium ASUS and ROG components.

ROG G1000

 

AniMe Holo: A New Era of Personalization

Beyond its raw power, the ROG G1000 is a visual masterpiece featuring the all-new AniMe Holo technology. This system utilizes full-color holographic projectors, allowing gamers to personalize their desktop like never before. The side panel showcases a massive 380mm holographic fan with 720 LEDs, complemented by dual 215mm fans on the front panel.

Despite their scale, these fans operate at a whisper-quiet 20.5 dBA within their sealed housings. With support for 16.77 million colors and full integration via Armoury Crate, users can display custom text, system stats, or complex animations, creating a truly one-of-a-kind gaming machine.

 

Flagship Power and Uncompromising Specs

At the heart of the G1000 lies the AMD Ryzen™ 7 9800X3D. Featuring 16 cores, 32 threads, and advanced 3D V-Cache™ technology, this processor is designed to dominate AAA titles and intensive multitasking. Slated for later this year, ROG G1000 will also come equipped with the option of up to AMD Ryzen™ 9 9950X3D to complement your build.

 

To complement this elite processing power, the G1000 can be equipped with our ROG Astral GeForce RTX™ 5080 GPU. The system is built on a high-end X870 motherboard, featuring robust power delivery, onboard high-speed wireless, and dedicated TPM module for hardware-level security. With ultra-fast DDR5 RAM and four M.2 PCIe slots for massive storage expansion, the G1000 is prepared for the most demanding workloads of today and tomorrow.

 

Revolutionary ROG Thermal Atrium

The ROG G1000 debuts the ROG Thermal Atrium, a breakthrough in desktop cooling. By isolating the 420mm AIO radiator and three 140mm intake fans in a separate chamber outside the main chassis, the CPU cooler gains direct access to ambient air that hasn’t been heated by the GPU or PSU. This innovative layout reduces CPU intake temperatures by up to 16°C (28.8°F), ensuring absolute stability during marathon gaming sessions.

 

Following this Tri-Zone philosophy, the GPU and PSU sections are also thermally shielded from one another. The GPU draws fresh air from the front intakes, while the PSU maintains its own airflow path from beneath the chassis. Collectively, the G1000 thermal system can dissipate over 1000W of heat, providing the thermal headroom necessary for next-generation hardware and extreme performance.

 

The Pinnacle of Gaming Engineering

The ROG G1000 is more than just a gaming desktop; it is a statement of engineering excellence. By combining the revolutionary Thermal Atrium with world-class components and the mesmerizing AniMe Holo display, ROG continues to set the standard for what a flagship PC can achieve. For gamers and creators who refuse to compromise, the G1000 stands alone at the peak of performance.

Availability & Pricing

The ROG GM1000 is are available for purchase today from ASUS Store and our retailer partners: Amazon, BestBuy, ExcaliburPC, Newegg, and MicroCenter.

 

Retailer	Where to Buy
ASUS Online	Link
Amazon	Link
ExcaliburPC	Link
Newegg	Link
Microcenter	Link

 

 

Press Contacts: 

ASUS USA PR Team: asuspr_usa@asus.com 

 

Notes to Editors

ASUS USA Pressroom: https://www.asus.com/us/news/         

ASUS USA Facebook: https://www.facebook.com/asus.n.america/     

ASUS USA X (Twitter): https://twitter.com/ASUSUSA     

 

 

SPECIFICATIONS

	ROG G1000
Design	104L ATX Ultra Tower with “Anime Holo” holographic fan
Processor	•        AMD Ryzen™ 7 9800X3D / AMD Ryzen™ 9 9950X3D (Later Nov.-Dec.)
Graphics	UMA: Supports AMD Ryzen™ G-series •        NVIDIA® GeForce® RTX5080
Platform	•        AMD® X870 Chipset
Thermal	•        420mm AIO with “ROG Thermal Atrium” Cooling Chamber
Memory	•        4x DDR5 U-DIMM slots, memory max up to 128GB
SATA	•        2 x SATA 6.0Gb/s ports
Storage	•        Up to 4TB M.2 2280 NVMe™ PCIe® 4.0 Performance SSD
Front I/O Ports	•        2 x USB3.2 Gen1 5Gbps TypeA •        1 x USB Type-C® 10Gbps •        1 x Microphone (Black) •        1 x Headphone (Black)
Rear I/O Ports	•        2 x USB4® (40Gbps) ports (2 x USB Type-C®) •        1 x USB 10Gbps port (1 x Type-A) •        3 x USB 5Gbps ports (3 x Type-A) •        4 x USB 2.0 ports (4 x Type-A)  •        1 x HDMI™ port •        1 x Wi-Fi module •        1 x Realtek 2.5Gb Ethernet port •        3 x Audio jacks
Power Supply	•        1000W power supply (80+ Gold)
Dimension	11.4 × 22.9 × 24.2 in (290 x 582.7 x 614.8mm)
Weight	(88.18 lbs)  40KG

 

### 

About ROG 

Republic of Gamers (ROG) is an ASUS sub-brand dedicated to creating the world’s best gaming hardware and software. Formed in 2006, ROG offers a complete line of innovative products known for performance and quality, including motherboards, graphics cards, system components, laptops, desktops, monitors, smartphones, audio equipment, routers, peripherals and accessories. ROG participates in and sponsors major international gaming events. ROG gear has been used to set hundreds of overclocking records and it continues to be the preferred choice of gamers and enthusiasts around the world. To become one of those who dare, learn more about ROG at http://rog.asus.com. 

 

 

Press Inquiries

Anthony Spence
asuspr_usa [at] asus.com
https://www.asus.com/
48720 Kato Road | Fremont, CA 94538

A video accompanying this announcement is available here: https://youtube.com/watch?v=LhC_zCKTc20

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA) today announced the launch of Realize ID, a sophisticated, unified mapping offering designed to help performance marketers capture and act on open-web intent as soon as it emerges. This identity offering has already driven up to 2.4x increase in conversion efficiency thanks to signal-enriched predicted intent models

Today’s performance marketers contend with a fragmented and rapidly changing consumer journey that stretches across devices, channels and content touchpoints. A single purchase decision now runs across mail, news, search, price aggregators, and increasingly LLMs. US adults spend nearly 13 hours a day with media, spread across dozens of devices and platforms, and a buyer passes through several of them before deciding. Generative AI search has become a new, essential channel for consumers to connect with brands organically and through advertising, adding to the complexity as well. Data shows that 70% of consumers now involve generative AI search in shopping decisions.

Realize ID is a unified identity solution that allows advertisers to understand, reach and drive conversions for consumers that show intent, across a fragmented internet. It is a new offering that supports the Realize performance advertising platform, fueled by Taboola’s unique access to data on consumer intent on the open web.

Realize ID transforms fragmented identifiers into a single, persistent view of high-intent prospects. It captures purchase intent while prospects are in active decision mode, the critical window after they’ve shown interest but before they’ve committed elsewhere. With this understanding of intent, advertisers can drive outcomes such as engagements, leads, purchases, site traffic and more. Taboola sits on both sides of the transaction, publisher and advertiser, operating a true closed loop, capturing full-context data on every single visit in real time.

To illustrate, Realize ID can help advertisers understand the consumer journey as they read a finance article on a publisher site, then search for the best bank accounts, view an ad for a credit card, arrive on a landing page to open an account, and more.

Realize ID leverages Taboola’s first-party data that captures the full context of the consumer journey, including:

• Media consumption signals: Content engagement, scroll depth, and time on site.
• Ad interactions: Ad clicks, video views, and specific search keywords.
• Buying behaviors: Conversion data and mid-funnel actions like starting a quote.

When combined, Realize ID understands billions of complete buyer journeys and uses advanced AI to connect media consumption and buying behaviors, predicting intent before it becomes obvious.

Brands and agencies continue to leverage the unique data advantage that Taboola and Realize offer.

• “Partnering with Taboola and using Realize has enhanced our ability to reach high-intent consumers at the right moment in their purchase journey. Their intent-driven technology helps us deliver more relevant advertising, improving campaign performance and supporting our growth objectives.”
  Judit Miranda, Head of Digital Marketing, El Corte Inglés.
  
• “In today’s market, trusted data is hard to come by, but Taboola and Realize bring decades of proven expertise to the table. Their insights allow us to meet consumers at critical intent moments during their buying journey with remarkable precision. We rely on their data to drive meaningful engagement and convert high-value prospects.”
  Sascha Arndt, Head of Performance Marketing at Ergo.
• “The value of Taboola and the data behind Realize lies in its ability to capture genuine purchase intent, not just casual browsing. Leveraging their trusted insights enables us to engage motivated buyers at the precise moment they are comparing options. The result is better alignment with consumer needs and improved conversion rates.”
  Sameer Jain, Head of E-commerce & D2C Business, Axis Max Life Insurance.
• “Taboola helps us identify audiences with genuine investment intent and engage them at the right moment. By leveraging its data insights, we can deliver more relevant experiences and drive stronger conversion outcomes.”
  Subendu Maity, AVP, Performance Marketing & Digital, Motilal Oswal Asset Management Co. Ltd.
• “Reaching consumers while they are actively searching for products is crucial, and Realize provides exactly the visibility we need during this phase. Their audience segments allow us to reach users with a high probability of converting at the precise moment when interest is strongest.”
  Romain Mandon, Digital Advertising Manager at Allianz.
• “At a time when the customer journey has grown very complex to stretch across devices and new channels and devices, including generative AI search, Realize has consistently shown it has the right data to tap into customer intent and connect us to our desired customers.”
  Adam Persinger, Head of Strategic Media, FOUND.
• “Overcoming the fragmentation of today’s purchase journey is one of the key challenges for performance marketers. Thanks to our strategic partnership with Taboola and the right technology, we’re able to capture users’ real intent wherever they move across the open web, with precision and efficiency. The launch of Realize ID is an opportunity we’re excited to seize, to deliver incremental, measurable results for our clients – beyond traditional search channels.”
  Giacomo Giuriani, Business Director at Forward, lastminute.com’s media marketing company.

“Today, AI is transforming traditional search behavior, and established channels are hitting efficiency ceilings, making driving incremental growth more difficult than ever. To scale today, performance marketers must connect with consumers across trusted environments beyond search and social. Buyers are actively researching, comparing, and forming decisions across dozens of independent content touchpoints. Realize ID solves for this, using Taboola’s unique data advantage, helping performance marketers capture and act on open web intent before it disappears,” said Adam Singolda, CEO at Taboola.

About Taboola
Taboola empowers businesses to grow through performance advertising technology that goes beyond search and social and delivers measurable outcomes at scale.

Taboola works with thousands of businesses who advertise directly on Realize, Taboola’s powerful ad platform, reaching over 600M daily active users across some of the best publishers in the world. Publishers like NBC News and Yahoo, and OEMs such as Samsung, Xiaomi and others use Taboola’s technology to grow audience and revenue, enabling Realize to offer unique data, specialized algorithms, and unmatched scale.

Disclaimer – Forward-Looking Statements
Taboola (the “Company”) may, in this communication, make certain statements that are not historical facts and relate to analysis or other information which are based on forecasts or future or results. Examples of such forward-looking statements include, but are not limited to, statements regarding future prospects, product development and business strategies. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements but are not the exclusive means for identifying such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that the predictions, forecasts, projections and other forward-looking statements will not be achieved. You should understand that a number of factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, including the risks set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 under Part 1, Item 1A “Risk Factors” and our subsequent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based

Contact
Dave Struzzi
Dave.s@taboola.com

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA) today announced the launch of Realize ID, a sophisticated, unified mapping offering designed to help performance marketers capture and act on open-web intent as soon as it emerges. This identity offering has already driven up to 2.4x increase in conversion efficiency thanks to signal-enriched predicted intent models

Today’s performance marketers contend with a fragmented and rapidly changing consumer journey that stretches across devices, channels and content touchpoints. A single purchase decision now runs across mail, news, search, price aggregators, and increasingly LLMs. US adults spend nearly 13 hours a day with media, spread across dozens of devices and platforms, and a buyer passes through several of them before deciding. Generative AI search has become a new, essential channel for consumers to connect with brands organically and through advertising, adding to the complexity as well. Data shows that 70% of consumers now involve generative AI search in shopping decisions.

Realize ID is a unified identity solution that allows advertisers to understand, reach and drive conversions for consumers that show intent, across a fragmented internet. It is a new offering that supports the Realize performance advertising platform, fueled by Taboola’s unique access to data on consumer intent on the open web.

Realize ID transforms fragmented identifiers into a single, persistent view of high-intent prospects. It captures purchase intent while prospects are in active decision mode, the critical window after they’ve shown interest but before they’ve committed elsewhere. With this understanding of intent, advertisers can drive outcomes such as engagements, leads, purchases, site traffic and more. Taboola sits on both sides of the transaction, publisher and advertiser, operating a true closed loop, capturing full-context data on every single visit in real time.

To illustrate, Realize ID can help advertisers understand the consumer journey as they read a finance article on a publisher site, then search for the best bank accounts, view an ad for a credit card, arrive on a landing page to open an account, and more.

Realize ID leverages Taboola’s first-party data that captures the full context of the consumer journey, including:

• Media consumption signals: Content engagement, scroll depth, and time on site.
• Ad interactions: Ad clicks, video views, and specific search keywords.
• Buying behaviors: Conversion data and mid-funnel actions like starting a quote.

When combined, Realize ID understands billions of complete buyer journeys and uses advanced AI to connect media consumption and buying behaviors, predicting intent before it becomes obvious.

Brands and agencies continue to leverage the unique data advantage that Taboola and Realize offer.

• “Partnering with Taboola and using Realize has enhanced our ability to reach high-intent consumers at the right moment in their purchase journey. Their intent-driven technology helps us deliver more relevant advertising, improving campaign performance and supporting our growth objectives.”
  Judit Miranda, Head of Digital Marketing, El Corte Inglés.
  
• “In today’s market, trusted data is hard to come by, but Taboola and Realize bring decades of proven expertise to the table. Their insights allow us to meet consumers at critical intent moments during their buying journey with remarkable precision. We rely on their data to drive meaningful engagement and convert high-value prospects.”
  Sascha Arndt, Head of Performance Marketing at Ergo.
• “The value of Taboola and the data behind Realize lies in its ability to capture genuine purchase intent, not just casual browsing. Leveraging their trusted insights enables us to engage motivated buyers at the precise moment they are comparing options. The result is better alignment with consumer needs and improved conversion rates.”
  Sameer Jain, Head of E-commerce & D2C Business, Axis Max Life Insurance.
• “Taboola helps us identify audiences with genuine investment intent and engage them at the right moment. By leveraging its data insights, we can deliver more relevant experiences and drive stronger conversion outcomes.”
  Subendu Maity, AVP, Performance Marketing & Digital, Motilal Oswal Asset Management Co. Ltd.
• “Reaching consumers while they are actively searching for products is crucial, and Realize provides exactly the visibility we need during this phase. Their audience segments allow us to reach users with a high probability of converting at the precise moment when interest is strongest.”
  Romain Mandon, Digital Advertising Manager at Allianz.
• “At a time when the customer journey has grown very complex to stretch across devices and new channels and devices, including generative AI search, Realize has consistently shown it has the right data to tap into customer intent and connect us to our desired customers.”
  Adam Persinger, Head of Strategic Media, FOUND.
• “Overcoming the fragmentation of today’s purchase journey is one of the key challenges for performance marketers. Thanks to our strategic partnership with Taboola and the right technology, we’re able to capture users’ real intent wherever they move across the open web, with precision and efficiency. The launch of Realize ID is an opportunity we’re excited to seize, to deliver incremental, measurable results for our clients – beyond traditional search channels.”
  Giacomo Giuriani, Business Director at Forward, lastminute.com’s media marketing company.

“Today, AI is transforming traditional search behavior, and established channels are hitting efficiency ceilings, making driving incremental growth more difficult than ever. To scale today, performance marketers must connect with consumers across trusted environments beyond search and social. Buyers are actively researching, comparing, and forming decisions across dozens of independent content touchpoints. Realize ID solves for this, using Taboola’s unique data advantage, helping performance marketers capture and act on open web intent before it disappears,” said Adam Singolda, CEO at Taboola.

About Taboola
Taboola empowers businesses to grow through performance advertising technology that goes beyond search and social and delivers measurable outcomes at scale.

Taboola works with thousands of businesses who advertise directly on Realize, Taboola’s powerful ad platform, reaching over 600M daily active users across some of the best publishers in the world. Publishers like NBC News and Yahoo, and OEMs such as Samsung, Xiaomi and others use Taboola’s technology to grow audience and revenue, enabling Realize to offer unique data, specialized algorithms, and unmatched scale.

Disclaimer – Forward-Looking Statements
Taboola (the “Company”) may, in this communication, make certain statements that are not historical facts and relate to analysis or other information which are based on forecasts or future or results. Examples of such forward-looking statements include, but are not limited to, statements regarding future prospects, product development and business strategies. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements but are not the exclusive means for identifying such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that the predictions, forecasts, projections and other forward-looking statements will not be achieved. You should understand that a number of factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, including the risks set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 under Part 1, Item 1A “Risk Factors” and our subsequent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based

Contact
Dave Struzzi
Dave.s@taboola.com

SAN DIEGO, Sept. 22, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that the financial advisors of Cornerstone Advisors and Clear Pointe Wealth Management have joined LPL Financial’s broker-dealer, Registered Investment Advisor (RIA) and custodial platforms. The teams reported serving approximately $1 billion in assets* and join LPL from Northwestern Mutual.

The two Salt Lake City, Utah area-based practices share a decades-long personal and professional relationship and are preparing to operate from a shared office while maintaining their distinct business identities. Together, the teams provide comprehensive financial planning and retirement-focused wealth management services to business owners, professionals and retirees throughout the region.

Meet Cornerstone Advisors

Led by financial advisors Gardner Brown and Brian Lifferth, CFP®, Cornerstone Advisors specializes in helping individuals and business owners nearing or living in retirement navigate complex financial decisions. Brown and Lifferth, who have worked together since 2004, have built the practice around a planning-first philosophy focused on helping clients prepare for and sustain retirement.

The team emphasizes comprehensive financial planning, investment management and coordination with other professionals, helping clients address retirement income, tax planning, estate considerations and wealth transfer needs.

“Financial planning has always been at the center of our practice,” said Brown. “For more than 30 years, we’ve helped clients navigate the decisions that come with retirement and major life transitions. We don’t just manage investments. We help clients address all the moving pieces of their financial lives and serve as a resource for them every step of the way.”

The team selected LPL for its advisor-focused culture, technology capabilities and flexibility to support future growth.

“LPL focuses on advisors so advisors can focus on clients,” said Lifferth. “The technology, investment capabilities, operational support and flexibility available through LPL position us to continue growing our practice while maintaining the personalized service our clients expect. We wanted a platform that could keep pace with the growth of our business and support where we want to go next.”

Supporting the practice are team members Lexie Sorensen, John Call III, Daniel Brown, Jennie Frey and Alexis Rowley.

Meet Clear Pointe Wealth Management

Clear Pointe Wealth Management is led by financial advisors Ron Hunt, CLU®, ChFC®, RICP®** and Jonathan Groberg, CLU®, ChFC®, CFP®, MSFS, who have worked together since 2005. The team serves clients who are preparing for retirement or living in retirement, with a particular focus on helping business owners and professionals translate thoughtful financial plans into actionable strategies.

Hunt and Groberg built their partnership around complementary skill sets, with Groberg focusing on investment research, portfolio construction and manager due diligence, while Hunt specializes in comprehensive planning and client strategy. Since joining forces, the practice has experienced significant growth and expanded its client relationships throughout the region.

“Our process starts with listening and building a comprehensive plan,” said Ron Hunt. “From there, we focus on implementation, helping ensure clients strategize and put strategies in place to support a successful retirement. It’s about turning a financial plan into a practical roadmap that clients can confidently follow.”

As the practice continued to grow, the team sought a platform that would enhance efficiency and provide expanded resources for clients.

“We were looking for a partner that would give us the tools, resources and flexibility needed to serve clients at the highest level,” Hunt said. “LPL’s technology, product breadth and service model will allow us to operate more efficiently and spend even more time focused on helping clients pursue their goals.”

Marc Cohen, chief growth officer at LPL Financial, said, “Cornerstone Advisors and Clear Pointe Wealth Management represent the kind of client-centric, planning-focused businesses that continue to elevate our industry. Gardner, Brian, Ron, and Jonathan have built firms with distinct identities, strong reputations, and enduring relationships. We are proud to welcome them to LPL and look forward to supporting their continued growth while helping them preserve the qualities that have contributed to their success.”

Outside of the office, the advisors have deep roots throughout Utah and remain actively involved in their local communities. The advisors have lived in Utah their entire lives and have expressed their commitment to continuing to serve Utah families and businesses for years to come.

Related

Advisors, learn how LPL Financial can help take your business to the next level.

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC. Cornerstone Advisors, Clear Pointe Wealth Management and LPL Financial are separate entities.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year, 2025.

** RICP conferred by The American College.​

Media Contact: 
Media.relations@LPLFinancial.com  

Tracking #1177083

SAN DIEGO, Sept. 22, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that the financial advisors of Cornerstone Advisors and Clear Pointe Wealth Management have joined LPL Financial’s broker-dealer, Registered Investment Advisor (RIA) and custodial platforms. The teams reported serving approximately $1 billion in assets* and join LPL from Northwestern Mutual.

The two Salt Lake City, Utah area-based practices share a decades-long personal and professional relationship and are preparing to operate from a shared office while maintaining their distinct business identities. Together, the teams provide comprehensive financial planning and retirement-focused wealth management services to business owners, professionals and retirees throughout the region.

Meet Cornerstone Advisors

Led by financial advisors Gardner Brown and Brian Lifferth, CFP®, Cornerstone Advisors specializes in helping individuals and business owners nearing or living in retirement navigate complex financial decisions. Brown and Lifferth, who have worked together since 2004, have built the practice around a planning-first philosophy focused on helping clients prepare for and sustain retirement.

The team emphasizes comprehensive financial planning, investment management and coordination with other professionals, helping clients address retirement income, tax planning, estate considerations and wealth transfer needs.

“Financial planning has always been at the center of our practice,” said Brown. “For more than 30 years, we’ve helped clients navigate the decisions that come with retirement and major life transitions. We don’t just manage investments. We help clients address all the moving pieces of their financial lives and serve as a resource for them every step of the way.”

The team selected LPL for its advisor-focused culture, technology capabilities and flexibility to support future growth.

“LPL focuses on advisors so advisors can focus on clients,” said Lifferth. “The technology, investment capabilities, operational support and flexibility available through LPL position us to continue growing our practice while maintaining the personalized service our clients expect. We wanted a platform that could keep pace with the growth of our business and support where we want to go next.”

Supporting the practice are team members Lexie Sorensen, John Call III, Daniel Brown, Jennie Frey and Alexis Rowley.

Meet Clear Pointe Wealth Management

Clear Pointe Wealth Management is led by financial advisors Ron Hunt, CLU®, ChFC®, RICP®** and Jonathan Groberg, CLU®, ChFC®, CFP®, MSFS, who have worked together since 2005. The team serves clients who are preparing for retirement or living in retirement, with a particular focus on helping business owners and professionals translate thoughtful financial plans into actionable strategies.

Hunt and Groberg built their partnership around complementary skill sets, with Groberg focusing on investment research, portfolio construction and manager due diligence, while Hunt specializes in comprehensive planning and client strategy. Since joining forces, the practice has experienced significant growth and expanded its client relationships throughout the region.

“Our process starts with listening and building a comprehensive plan,” said Ron Hunt. “From there, we focus on implementation, helping ensure clients strategize and put strategies in place to support a successful retirement. It’s about turning a financial plan into a practical roadmap that clients can confidently follow.”

As the practice continued to grow, the team sought a platform that would enhance efficiency and provide expanded resources for clients.

“We were looking for a partner that would give us the tools, resources and flexibility needed to serve clients at the highest level,” Hunt said. “LPL’s technology, product breadth and service model will allow us to operate more efficiently and spend even more time focused on helping clients pursue their goals.”

Marc Cohen, chief growth officer at LPL Financial, said, “Cornerstone Advisors and Clear Pointe Wealth Management represent the kind of client-centric, planning-focused businesses that continue to elevate our industry. Gardner, Brian, Ron, and Jonathan have built firms with distinct identities, strong reputations, and enduring relationships. We are proud to welcome them to LPL and look forward to supporting their continued growth while helping them preserve the qualities that have contributed to their success.”

Outside of the office, the advisors have deep roots throughout Utah and remain actively involved in their local communities. The advisors have lived in Utah their entire lives and have expressed their commitment to continuing to serve Utah families and businesses for years to come.

Related

Advisors, learn how LPL Financial can help take your business to the next level.

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC. Cornerstone Advisors, Clear Pointe Wealth Management and LPL Financial are separate entities.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year, 2025.

** RICP conferred by The American College.​

Media Contact: 
Media.relations@LPLFinancial.com  

Tracking #1177083

Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer

Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months in a selected pancreatic patient population versus 12.5 months in historical controls

OCALA, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a letter to stockholders from Chief Executive Officer Thomas Equels addressing the recent U.S. Food and Drug Administration (the “FDA”) approval of daraxonrasib and outlining the Company’s view of Ampligen’s differentiated mechanism, clinical profile and potential role in the future treatment of pancreatic cancer.

The full letter follows:

Dear Fellow Stockholders,

The FDA’s recent approval of daraxonrasib is meaningful progress for people with metastatic pancreatic cancer. In fact, it is significant enough that you may be asking – and I should answer – two questions:

Question 1: How is AIM’s drug Ampligen^® different from daraxonrasib?

Daraxonrasib is a selective, targeted therapy that inhibits RAS, a major driver of pancreatic cancer. A pivotal, randomized, well-controlled study demonstrated median overall survival of 13.2 months with daraxonrasib compared to 6.7 months with standard chemotherapy, for an improvement of 6.5 months (See Figure 1 below, NEJM). These results are an important part of the basis for the FDA’s approval of daraxonrasib, but they also indicate that many patients on both daraxonrasib and on standard therapy experience disease progression and mortality. Further, in laboratory studies, pancreatic tumors have been seen to develop resistance to RAS inhibition.

Ampligen has a different mechanism of action from daraxonrasib. We believe that Ampligen is the only clinically advanced investigational TLR3 agonist with a well-developed safety profile that is designed to activate innate immunity and help therapeutically reshape the tumor microenvironment to provide a natural mechanism to eliminate cancer cells. While daraxonrasib directly inhibits one driver mutation related to pancreatic cancer, Ampligen has the potential to induce a broad-spectrum therapeutic effect that amplifies a patient’s innate immune system, with data suggesting the potential for consequent stabilization of the pancreatic cancer tumor immune responses with improvement in a patient’s Quality of Life. We have seen evidence of this therapeutic potential not only in pancreatic cancer, but in a range of other solid tumors.

Question 2: What role will Ampligen serve in the future of pancreatic cancer care?

Daraxonrasib is an important therapeutic advance, but pancreatic cancer is not a simple disease where one successful targeted drug makes additional therapeutic development unnecessary. We believe Ampligen has the potential to complement and extend therapies such as daraxonrasib by helping to overcome the immune biological barriers that have historically limited treatment success in pancreatic cancer.

Further, we believe that Ampligen has significant potential in pancreatic cancer as a monotherapy. In an analysis of patients with a blood neutrophil-to-lymphocyte ratio below 4.5 who participated in a Dutch government-approved Named Patient Program, Ampligen as a monotherapy was linked to a median overall survival of 34.8 months compared with only 12.5 months in well-matched historical controls, representing an observed increase in median overall survival of 22.3 months over the historical controls (See Figure 2 below, AIMImmuno.com).

The accompanying chart visually summarizes the respective overall-survival results cited in this letter, including the separate control and treatment comparisons for daraxonrasib and Ampligen based on the separate cited datasets.

In conclusion, daraxonrasib’s approval does not preclude a potentially important role for Ampligen. Daraxonrasib targets a single driver of pancreatic cancer, while Ampligen is designed to work by activating and enhancing the body’s innate immune system to target multiple types of solid tumors, including cancers of the pancreas. Based on all that we know to date, we believe that Ampligen continues to have an important potential role to serve in pancreatic cancer treatment.

AIM is also invested in Ampligen’s potential as a part of a combination therapy with checkpoint inhibitors in a broad range of other solid tumors, including pancreatic cancer. The ongoing Phase 2 DURIPANC clinical trial is evaluating Ampligen with AstraZeneca’s durvalumab (Imfinzi) in patients whose pancreatic cancer was stable post-FOLFIRINOX. This is an exploratory, open-label, single-center study with a small number of patients. Its primary endpoint is the proportion of patients who have stable disease or a tumor response 24 weeks after combination treatment begins. We anticipate topline results from the DURIPANC study in Q1 2027, followed by a detailed analysis of overall survival in Q3 2027. AIM believes that Ampligen’s observed immune activity will translate into a meaningful clinical signal and allow us to establish the parameters of a follow-up, pivotal Phase 3 clinical trial.

While there is still work to be done, including rigorous pivotal trials, our goal remains clear: to determine whether Ampligen can contribute to longer and better lives for patients with pancreatic cancer. We believe it can.

AIM appreciates your continued support as we pursue that goal with scientific discipline and a clear understanding of what still must be proven.

Thomas K. Equels
Chief Executive Officer
AIM ImmunoTech Inc.

References:

• Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses (2024)
• Rintatolimod: A potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3 (2023)
• Rintatolimod (Ampligen^®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program (2022)
• Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients? (2021)
• AIM ImmunoTech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer (2020)
• AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer (2021)
• Ampligen Breakthroughs in Treating Pancreatic Cancer (2025)
• Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (2026)

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen^® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating to: Ampligen’s potential to reshape the pancreatic tumor microenvironment and to enhance the activity of PD-1 and PD-L1 checkpoint inhibitors, including pembrolizumab and durvalumab; the potential for any such effect to be durable or long-lasting; Ampligen’s potential to complement existing therapies and to overcome biological barriers that have limited treatment success in pancreatic cancer; the potential of the Phase 2 DURIPANC study to inform patient selection, biomarker identification and the design of a potential future pivotal development program; the timing, conduct and outcome of the DURIPANC primary endpoint analyses, biomarker evaluations and overall survival follow-up; the timing and outcome of planned regulatory interactions; intellectual property expansion; the Company’s long-term pancreatic cancer development strategy and its efforts to position Ampligen for the next stage of development; and the Company’s ability to create long-term value for its stockholders. Forward-looking statements include statements attributed to, or made by, the Company’s Chief Executive Officer in the letter above. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen^® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen^® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/53bfb7cd-009a-4cc0-9b40-c044efef4b9c

CONTACT: Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer

Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months in a selected pancreatic patient population versus 12.5 months in historical controls

OCALA, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a letter to stockholders from Chief Executive Officer Thomas Equels addressing the recent U.S. Food and Drug Administration (the “FDA”) approval of daraxonrasib and outlining the Company’s view of Ampligen’s differentiated mechanism, clinical profile and potential role in the future treatment of pancreatic cancer.

The full letter follows:

Dear Fellow Stockholders,

The FDA’s recent approval of daraxonrasib is meaningful progress for people with metastatic pancreatic cancer. In fact, it is significant enough that you may be asking – and I should answer – two questions:

Question 1: How is AIM’s drug Ampligen^® different from daraxonrasib?

Daraxonrasib is a selective, targeted therapy that inhibits RAS, a major driver of pancreatic cancer. A pivotal, randomized, well-controlled study demonstrated median overall survival of 13.2 months with daraxonrasib compared to 6.7 months with standard chemotherapy, for an improvement of 6.5 months (See Figure 1 below, NEJM). These results are an important part of the basis for the FDA’s approval of daraxonrasib, but they also indicate that many patients on both daraxonrasib and on standard therapy experience disease progression and mortality. Further, in laboratory studies, pancreatic tumors have been seen to develop resistance to RAS inhibition.

Ampligen has a different mechanism of action from daraxonrasib. We believe that Ampligen is the only clinically advanced investigational TLR3 agonist with a well-developed safety profile that is designed to activate innate immunity and help therapeutically reshape the tumor microenvironment to provide a natural mechanism to eliminate cancer cells. While daraxonrasib directly inhibits one driver mutation related to pancreatic cancer, Ampligen has the potential to induce a broad-spectrum therapeutic effect that amplifies a patient’s innate immune system, with data suggesting the potential for consequent stabilization of the pancreatic cancer tumor immune responses with improvement in a patient’s Quality of Life. We have seen evidence of this therapeutic potential not only in pancreatic cancer, but in a range of other solid tumors.

Question 2: What role will Ampligen serve in the future of pancreatic cancer care?

Daraxonrasib is an important therapeutic advance, but pancreatic cancer is not a simple disease where one successful targeted drug makes additional therapeutic development unnecessary. We believe Ampligen has the potential to complement and extend therapies such as daraxonrasib by helping to overcome the immune biological barriers that have historically limited treatment success in pancreatic cancer.

Further, we believe that Ampligen has significant potential in pancreatic cancer as a monotherapy. In an analysis of patients with a blood neutrophil-to-lymphocyte ratio below 4.5 who participated in a Dutch government-approved Named Patient Program, Ampligen as a monotherapy was linked to a median overall survival of 34.8 months compared with only 12.5 months in well-matched historical controls, representing an observed increase in median overall survival of 22.3 months over the historical controls (See Figure 2 below, AIMImmuno.com).

The accompanying chart visually summarizes the respective overall-survival results cited in this letter, including the separate control and treatment comparisons for daraxonrasib and Ampligen based on the separate cited datasets.

In conclusion, daraxonrasib’s approval does not preclude a potentially important role for Ampligen. Daraxonrasib targets a single driver of pancreatic cancer, while Ampligen is designed to work by activating and enhancing the body’s innate immune system to target multiple types of solid tumors, including cancers of the pancreas. Based on all that we know to date, we believe that Ampligen continues to have an important potential role to serve in pancreatic cancer treatment.

AIM is also invested in Ampligen’s potential as a part of a combination therapy with checkpoint inhibitors in a broad range of other solid tumors, including pancreatic cancer. The ongoing Phase 2 DURIPANC clinical trial is evaluating Ampligen with AstraZeneca’s durvalumab (Imfinzi) in patients whose pancreatic cancer was stable post-FOLFIRINOX. This is an exploratory, open-label, single-center study with a small number of patients. Its primary endpoint is the proportion of patients who have stable disease or a tumor response 24 weeks after combination treatment begins. We anticipate topline results from the DURIPANC study in Q1 2027, followed by a detailed analysis of overall survival in Q3 2027. AIM believes that Ampligen’s observed immune activity will translate into a meaningful clinical signal and allow us to establish the parameters of a follow-up, pivotal Phase 3 clinical trial.

While there is still work to be done, including rigorous pivotal trials, our goal remains clear: to determine whether Ampligen can contribute to longer and better lives for patients with pancreatic cancer. We believe it can.

AIM appreciates your continued support as we pursue that goal with scientific discipline and a clear understanding of what still must be proven.

Thomas K. Equels
Chief Executive Officer
AIM ImmunoTech Inc.

References:

• Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses (2024)
• Rintatolimod: A potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3 (2023)
• Rintatolimod (Ampligen^®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program (2022)
• Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients? (2021)
• AIM ImmunoTech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer (2020)
• AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer (2021)
• Ampligen Breakthroughs in Treating Pancreatic Cancer (2025)
• Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (2026)

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen^® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating to: Ampligen’s potential to reshape the pancreatic tumor microenvironment and to enhance the activity of PD-1 and PD-L1 checkpoint inhibitors, including pembrolizumab and durvalumab; the potential for any such effect to be durable or long-lasting; Ampligen’s potential to complement existing therapies and to overcome biological barriers that have limited treatment success in pancreatic cancer; the potential of the Phase 2 DURIPANC study to inform patient selection, biomarker identification and the design of a potential future pivotal development program; the timing, conduct and outcome of the DURIPANC primary endpoint analyses, biomarker evaluations and overall survival follow-up; the timing and outcome of planned regulatory interactions; intellectual property expansion; the Company’s long-term pancreatic cancer development strategy and its efforts to position Ampligen for the next stage of development; and the Company’s ability to create long-term value for its stockholders. Forward-looking statements include statements attributed to, or made by, the Company’s Chief Executive Officer in the letter above. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen^® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen^® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/53bfb7cd-009a-4cc0-9b40-c044efef4b9c

CONTACT: Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

Strong pace of patient enrollment supports continued advancement toward regulatory milestones

Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5% disease control rate (DCR) in heavily pretreated NSCLC

CHICAGO, Sept. 22, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that enrollment has reached 65 patients in its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targeting therapy as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC). The THIO-104 trial currently has 38 trial sites activated in 6 foreign countries (Taiwan, Romania, Turkey, Georgia, Poland and Hungary).

“Reaching 65 randomized patients marks an important milestone in our Phase 3 trial. With additional clinical sites expected to begin enrolling patients, we remain on track to achieve our goal of more than 100 randomized patients by year-end,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “As we’ve stated previously, statistical assessments of the Phase 3 trial point to a very high probability of technical success for regulatory approval of ateganosine.¹ We believe third-line NSCLC is an excellent market entry segment due to the substantial unmet medical need in this large immunotherapy-resistant and chemotherapy-resistant population. No current standard of care exists in this NSCLC treatment setting and competition for clinical trial patients is limited.”

In its most recent assessment, ateganosine sequenced with a checkpoint inhibitor showed 90.5% interim disease control rate (DCR) in heavily pretreated 3L NSCLC in MAIA’s ongoing phase 2 THIO-101 clinical trial. This measure contrasts with reported 25%–35% DCRs for standard third-line chemotherapy regimens.

In July 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for ateganosine for the treatment of NSCLC. This designation allows for more frequent FDA communication, potential rolling review, and eligibility for Accelerated Approval and Priority Review. If approved, ateganosine will hold FDA New Chemical Entity (NCE) five-year marketing exclusivity. An NCE is a small molecule drug with a novel active ingredient that hasn’t been previously approved or marketed.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

About THIO-104 Phase 3 Clinical Trial

THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. For more information on this Phase 3 trial, please visit ClinicalTrials.gov using the identifier NCT06908304.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

---

¹ See latest MAIA investor presentation and 2026 shareholder letter at ir.maiabiotech.com/company-information/presentations.

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:			Mothercare PLC
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights							X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name			Lombard Odier Asset Management (Europe) Limited
City and country of registered office (if applicable)			London, United Kingdom
4. Full name of shareholder(s) (if different from 3.) v
Name			Disclosure on behalf of accounts managed on a discretionary basis by Lombard Odier Investment Managers group.
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached vi:			18.09.2026
6. Date on which issuer notified (DD/MM/YYYY):			22.09.2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached	0.0%			0.0%		0
Position of previous notification (if applicable)	18.93%			18.93%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
GB0009067447				0					0.0%
SUBTOTAL 8. A		0					0.0%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date x	Exercise/ Conversion Period xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
			SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date x		Exercise/ Conversion Period xi		Physical or cash Settlement xii			Number of voting rights	% of voting rights
					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii				X
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi

Place of completion	London, United Kingdom
Date of completion	22.09.2026